Vielot Nadja A, Goldberg Shoshana K, Zimet Gregory, Smith Sara B, Anne McDonald Mary, Ramos Silvina, Morgan Karen, Joo Kim Chan, Richter Karin L, Peris Merce, Whaley Kevin J, Smith Jennifer S
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, CB# 7435, Chapel Hill, NC 27599, USA.
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, CB# 7435, Chapel Hill, NC 27599, USA.
Papillomavirus Res. 2017 Jun;3:126-133. doi: 10.1016/j.pvr.2017.04.001. Epub 2017 Apr 6.
Multipurpose vaccines (MPVs) could be formulated to prevent multiple sexually transmitted infections simultaneously. Little is known about acceptability of MPVs among vaccine health care providers (HCPs) or mothers of adolescent girls.
151 adolescent vaccine providers and 118 mothers of adolescent girls aged 9-14 were recruited from five geographically-diverse countries: Argentina, Malaysia, South Africa, South Korea, and Spain. We assessed providers' preferences for single-purpose human papillomavirus (HPV) vaccine versus MPVs (including HPV+herpes simplex virus (HSV)-2, HPV+HIV, or HPV+HSV-2+HIV) via quantitative surveys. Maternal MPV attitudes were assessed in four focus group discussions (FGDs) in each country.
Most providers preferred MPVs over single-purpose HPV vaccination, with preference ranging from 61% in Malaysia to 96% in South Africa. HPV+HSV-2+HIV was the most preferred MPV formulation (56-82%). Overall, 53% of the mothers preferred MPVs over single-purpose HPV vaccines, with strongest support in South Africa (90%) and lowest support in South Korea (29%). Convenience and trust in the health care system were commonly-cited reasons for MPV acceptability. Safety and efficacy concerns were common barriers to accepting MPVs, though specific concerns differed by country. Across FGDs, additional safety and efficacy information on MPVs were requested, particularly from trusted sources like HCPs.
Though maternal acceptability of MPVs varied by country, MPV acceptability would be enhanced by having HCPs provide parents with additional MPV vaccine safety and efficacy information. While most providers preferred MPVs, future health behavior research should identify acceptability barriers, and targeted provider interventions should equip providers to improve vaccination discussions with parents.
多用途疫苗（MPV）可被设计用于同时预防多种性传播感染。关于多用途疫苗在疫苗医疗保健提供者（HCP）或青春期女孩母亲中的可接受性，人们了解甚少。
从五个地理位置不同的国家招募了151名青少年疫苗提供者和118名9至14岁青春期女孩的母亲，这五个国家分别是阿根廷、马来西亚、南非、韩国和西班牙。我们通过定量调查评估了提供者对单一用途人乳头瘤病毒（HPV）疫苗与多用途疫苗（包括HPV + 单纯疱疹病毒2型（HSV）、HPV + 人类免疫缺陷病毒（HIV）或HPV + HSV - 2 + HIV）的偏好。在每个国家的四次焦点小组讨论（FGD）中评估了母亲对多用途疫苗的态度。
大多数提供者更喜欢多用途疫苗而非单一用途HPV疫苗，偏好程度从马来西亚的61%到南非的96%不等。HPV + HSV - 2 + HIV是最受欢迎的多用途疫苗配方（56 - 82%）。总体而言，53%的母亲更喜欢多用途疫苗而非单一用途HPV疫苗，在南非支持率最高（90%），在韩国支持率最低（29%）。便利性和对医疗保健系统的信任是多用途疫苗可接受性的常见原因。对安全性和有效性的担忧是接受多用途疫苗的常见障碍，不过具体担忧因国家而异。在所有焦点小组讨论中，都要求提供关于多用途疫苗的更多安全性和有效性信息，特别是来自像医疗保健提供者这样可信赖来源的信息。
尽管母亲对多用途疫苗的可接受性因国家而异，但医疗保健提供者向家长提供更多多用途疫苗的安全性和有效性信息会提高多用途疫苗的可接受性。虽然大多数提供者更喜欢多用途疫苗，但未来的健康行为研究应确定可接受性障碍，有针对性的提供者干预措施应使提供者有能力改善与家长的疫苗接种讨论。
